Share on StockTwits

Advanced Oncotherapy PLC (LON:AVO)‘s stock had its “speculative buy” rating restated by equities researchers at Beaufort Securities in a research report issued on Monday.

AVO has been the subject of a number of other recent research reports. Analysts at Westhouse Securities reiterated a “buy” rating on shares of Advanced Oncotherapy PLC in a research note on Tuesday, July 22nd. They now have a GBX 9 ($0.15) price target on the stock.

Advanced Oncotherapy PLC (LON:AVO) traded down 0.68% during mid-day trading on Monday, hitting GBX 3.65. The stock had a trading volume of 447,617 shares. Advanced Oncotherapy PLC has a one year low of GBX 2.25 and a one year high of GBX 4.00. The stock’s 50-day moving average is GBX 3.21 and its 200-day moving average is GBX 2.95.

Advanced Oncotherapy PLC is a United Kingdom-based specialist developer and provider of the particle therapy systems with protons that makes radiation less toxic for patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.